New hope to halt deadly lung scarring
NCT ID NCT06714123
Summary
This study is testing whether a drug called Senicapoc can slow the progression of scarring in the lungs for people with fibrotic interstitial lung disease (ILD) or idiopathic pulmonary fibrosis (IPF). About 140 participants will take either Senicapoc or a placebo pill three times a day for 26 weeks, in addition to their usual care, to see if it helps preserve lung function. Researchers will monitor lung capacity, walking ability, quality of life, and safety over one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
RECRUITINGAarhus N, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Odense University Hospital
NOT_YET_RECRUITINGOdense C, 5000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tartu University Hospital,
NOT_YET_RECRUITINGTartu, 50406, Estonia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.